Health condition
Pulmonary arterial hypertension deep dive
Pulmonary arterial hypertension (PAH) is a rare disease of the small lung arteries that raises pressure and strains the right heart; diagnosis requires right heart catheterisation, and modern combination therapy has transformed the outlook.
Why trust this guide
- 01
Editorial team
Written by our editorial team from the UK sources listed on each page.
- 02
Sourced from guidance
Checked against current NHS and UK specialist society guidance at the time of review.
- 03
Current for 2026
Reviewed on 2026-09-27 with the next review scheduled for 2027-09-27.
Key points
What matters most, at a glance.
The essentials in plain English - symptoms, when to seek help, who to see and what treatment looks like.
-
Unexplained breathlessness on exertion is the cardinal symptom, often attributed to asthma or unfitness for months or years
-
Echocardiography raises suspicion, but right heart catheterisation at a specialist centre is required to confirm PAH
-
Causes include idiopathic disease, heritable forms (often BMPR2 variants), connective tissue disease and congenital heart disease
-
Upfront combination therapy - typically an endothelin receptor antagonist plus a PDE-5 inhibitor - is standard, with prostanoids and newer agents added by risk
-
Care is organised around a small number of national centres with structured risk assessment at every visit
Understanding it
About Pulmonary arterial hypertension deep dive, and what to do next.
In PAH the smallest lung arteries thicken and narrow, forcing the right ventricle to pump against escalating resistance. The lungs sound clear and basic tests can be normal, which explains the notorious diagnostic delay; the clue is breathlessness disproportionate to everything else, sometimes with exertional light-headedness or fainting.
Once confirmed, treatment is risk-stratified and escalated proactively, aiming for low-risk status rather than mere stability. Heritable and drug-induced forms are actively sought, relatives are offered counselling where a gene variant is found, and CTEPH - a surgically curable mimic - is excluded in every patient with a V/Q scan. Most people start with their GP, who can refer to one of the UK’s designated specialist pulmonary hypertension centres. In many parts of the UK, routine NHS referrals for this kind of problem currently take 20-45+ weeks, whereas an initial private consultation is typically available within around two weeks.
A quiet reminder
This guide is for information, not medical advice.
Your GP knows your history and can tell you which parts apply to you. If in doubt, see them - and seek urgent care for any emergency symptoms described above.
Frequently asked
Common questions about Pulmonary arterial hypertension deep dive.
Quick, plain-English answers to what people ask us most.
-
What is pulmonary arterial hypertension?
Pulmonary arterial hypertension (PAH) is high blood pressure specifically within the arteries supplying the lungs, caused by narrowing and thickening of these small blood vessels, which puts strain on the right side of the heart.
-
What causes pulmonary arterial hypertension?
It can occur without a clear cause (idiopathic), be inherited, or develop secondary to connective tissue diseases, congenital heart disease, certain drugs, or HIV infection, each affecting the lung blood vessels through somewhat different mechanisms.
-
What are the symptoms?
Breathlessness, particularly with exertion, fatigue, chest pain, and, in more advanced disease, swelling of the legs and fainting are typical, often developing gradually and sometimes mistaken for less serious conditions initially.
-
Is pulmonary arterial hypertension dangerous?
Yes, it's a serious, progressive condition that puts significant strain on the heart over time, though modern targeted treatments have considerably improved outlook and quality of life for many patients.
-
Can pulmonary arterial hypertension be treated?
Yes, several classes of specific medications targeting the underlying blood vessel narrowing are available, often used in combination, alongside supportive treatments and, for suitable candidates, lung transplantation in advanced disease.
-
How is pulmonary arterial hypertension diagnosed?
An echocardiogram often raises initial suspicion, with right heart catheterisation (measuring pressures directly) needed to confirm the diagnosis and assess severity, alongside tests to identify any underlying cause.
-
How long does treatment take to show benefit?
Specific PAH medications often show improvement in symptoms and exercise capacity within weeks to a few months, with treatment typically needing to continue long-term to maintain control.
-
Pulmonary arterial hypertension vs pulmonary hypertension generally — what's the difference?
Pulmonary hypertension is the broad term for raised blood pressure in the lung arteries from any cause, while pulmonary arterial hypertension specifically refers to one particular group of causes involving direct disease of the small pulmonary arteries, requiring right heart catheterisation to properly classify.
-
What is the outlook for pulmonary arterial hypertension?
Outlook has improved considerably with modern targeted therapies, though it remains a serious, life-limiting condition for many; the specific outlook varies depending on the underlying cause and how well the condition responds to treatment.
-
When should I see a specialist, and how quickly can I be seen privately?
See a cardiologist or respiratory specialist for unexplained progressive breathlessness. Private specialist assessment is typically available within about two weeks, faster than standard NHS referral pathways for this condition.